Black Diamond Therapeutics, Inc. (BDTX)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
1.90 USD
-0.01
(-0.524%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.88 -0.02 (-0.020%) ⇩ (July 13, 2026, 5:56 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:52 a.m. EDT
The investment case for Black Diamond Therapeutics is currently defined by a severe disconnect between its fragile financial reality and its speculative biotech potential. Fundamentally, the company is in distress: it has burned through nearly 92% of its value over the last five years, carries negative earnings and cash flow, and lacks a dividend to cushion investors. While the balance sheet shows a high current ratio due to significant cash reserves, the relentless burn rate and lack of profitability suggest these funds are merely delaying the inevitable need for capital raises or dilution. The short-term outlook remains precarious. Although recent news highlights positive Phase 2 results and a Q1 earnings beat, the stock has failed to capitalize on this momentum, trading well below its moving averages and showing a negative adjusted forecast. The options market confirms this skepticism, with traders aggressively buying deep puts to hedge against further declines, while call volume is negligible. This suggests that even the optimistic catalysts of clinical progress are insufficient to overcome the market's fear of the company's deteriorating financial trajectory. Until there is undeniable proof of a sustainable path to profitability or a definitive acquisition offer, the risk-reward profile leans heavily toward caution. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.222636 |
| AutoARIMA | 0.224939 |
| AutoETS | 0.224939 |
| MSTL_126 | 0.225036 |
| MSTL | 0.235227 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 14.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.106 |
| Excess Kurtosis | -1.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 17.145 |
| Market Cap | 108,873,376 |
| Forward P/E | -1.64 |
| Beta | 3.25 |
| Website | https://www.blackdiamondtherapeutics.com |
As of July 11, 2026, 5:52 a.m. EDT: Speculators are heavily positioned for downside protection, with deep out-of-the-money puts dominating open interest across September and December expirations. Call activity is sparse and concentrated near the money, while implied volatility for puts remains significantly elevated compared to calls, indicating a market pricing in substantial downside risk rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.35034013 |
| Address1 | 245 First Street |
| Address2 | 18th Floor |
| All Time High | 46.25 |
| All Time Low | 1.18 |
| Ask | 2.35 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 2,512,370 |
| Average Daily Volume3 Month | 1,778,975 |
| Average Volume | 1,778,975 |
| Average Volume10Days | 2,512,370 |
| Beta | 3.252 |
| Bid | 1.42 |
| Bid Size | 2 |
| Book Value | 1.82 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.9 |
| Current Ratio | 8.461 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.978 |
| Day Low | 1.83 |
| Debt To Equity | 17.145 |
| Display Name | Black Diamond Therapeutics |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -45,654,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.186 |
| Enterprise Value | 8,497,371 |
| Eps Current Year | -0.63167 |
| Eps Forward | -1.162 |
| Eps Trailing Twelve Months | -0.78 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.2492 |
| Fifty Day Average Change | -0.34920013 |
| Fifty Day Average Change Percent | -0.15525526 |
| Fifty Two Week Change Percent | -35.03401 |
| Fifty Two Week High | 4.94 |
| Fifty Two Week High Change | -3.04 |
| Fifty Two Week High Change Percent | -0.6153846 |
| Fifty Two Week Low | 1.6 |
| Fifty Two Week Low Change | 0.29999995 |
| Fifty Two Week Low Change Percent | 0.18749997 |
| Fifty Two Week Range | 1.6 - 4.94 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,580,481,000,000 |
| Float Shares | 52,449,460 |
| Forward Eps | -1.162 |
| Forward P E | -1.6351119 |
| Free Cashflow | -25,891,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 21 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | 0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00651 |
| Held Percent Institutions | 0.67238 |
| Implied Shares Outstanding | 57,301,774 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Black Diamond Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 108,873,376 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_424913244 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -43,211,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 109,159,879 |
| Number Of Analyst Opinions | 7 |
| Open | 1.89 |
| Operating Cashflow | -34,028,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 617 252 0848 |
| Post Market Change | -0.01999998 |
| Post Market Change Percent | -1.0526305 |
| Post Market Price | 1.88 |
| Post Market Time | 1,783,979,816 |
| Previous Close | 1.91 |
| Price Eps Current Year | -3.0078998 |
| Price Hint | 4 |
| Price To Book | 1.043956 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 8.137 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.00999999 |
| Regular Market Change Percent | -0.52356 |
| Regular Market Day High | 1.978 |
| Regular Market Day Low | 1.83 |
| Regular Market Day Range | 1.83 - 1.978 |
| Regular Market Open | 1.89 |
| Regular Market Previous Close | 1.91 |
| Regular Market Price | 1.9 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 822,355 |
| Return On Assets | -0.18566 |
| Return On Equity | -0.35157 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 57,301,774 |
| Shares Percent Shares Out | 0.078600004 |
| Shares Short | 4,502,074 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 6,033,281 |
| Short Name | Black Diamond Therapeutics, Inc |
| Short Percent Of Float | 0.113000005 |
| Short Ratio | 2.31 |
| Source Interval | 15 |
| State | MA |
| Symbol | BDTX |
| Target High Price | 14.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 9.85714 |
| Target Median Price | 10.0 |
| Total Cash | 118,258,000 |
| Total Cash Per Share | 2.064 |
| Total Debt | 17,882,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.78 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.787175 |
| Two Hundred Day Average Change | -0.88717496 |
| Two Hundred Day Average Change Percent | -0.31830618 |
| Type Disp | Equity |
| Volume | 822,355 |
| Website | https://www.blackdiamondtherapeutics.com |
| Zip | 2,142 |